Evidence map›Paper›PMID 36400540›Full record

ReviewHematology/oncology clinics of North America2022

The Cardiopulmonary Complications of Sickle Cell Disease.

Ankit A Desai, Roberto F Machado, Robyn T Cohen

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology/oncology clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The role of the pulmonary function laboratory in the management of hematologic diseases.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Ankit A DesaiDepartment of Medicine, Indiana School of Medicine, Indianapolis, IN, USA; Indiana University, 950 W. Walnut Street R2 Building, Room 466, Indianapolis, IN 46202, USA.
Roberto F MachadoDivision of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, Room C400, Walther Hall, R3 980 W. Walnut Street, Indianapolis, IN 46202, USA.
Robyn T CohenDepartment of Pediatrics, Boston Medical Center/Boston University School of Medicine, 801 Albany Street 4th Floor, Boston, MA 02118, USA. Electronic address: robyn.cohen@bmc.org.
Boston Medical Center · USIndiana University – Purdue University Indianapolis · USWalther Cancer Foundation · US

Funding

Vascular Targeting Genomic & Genetic Strategies for Acute Chest SyndromeR01HL111656 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Roberto F. Machado · 2013 to 2026
$7.9M
Role of Sphingolipid Pathways in the Pathobiology of PAHR01HL127342 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MACHADO, ROBERTO F., NATARAJAN, VISWANATHAN · 2016 to 2023
$4.5M
NAD-dependent Signaling and Pulmonary Vascular Remodeling in PAHR01HL158108 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MACHADO, ROBERTO F. · 2022 to 2025
$2.9M
Pathogenic Role of IL-18 in Sickle Cell Cardiomyopathy and Inducible Ventricular TachycardiaR01HL136603 · NHLBI · UNIVERSITY OF ARIZONA · PI DESAI, ANKIT A · 2017 to 2021
$2.4M
NHLBI NIH HHS R01 HL111656NHLBI NIH HHS R01 HL127342NHLBI NIH HHS R01 HL136603NHLBI NIH HHS R01 HL158108
6 · The paper itself

Abstract

Sickle cell disease (SCD) is a genetic hemoglobinopathy associated with extensive morbidity and early mortality. While there have been recent improvements in available disease-modifying therapies for SCD, cardiopulmonary complications remain a major risk factor for death in this population. We provide an overview of current knowledge regarding several of the major acute and chronic cardiopulmonary complications in SCD, including: acute chest syndrome, airway disease, lung function abnormalities, nocturnal hypoxemia and sleep disordered breathing, pulmonary vascular disease, and sickle cell cardiomyopathy.

Indexed as

Anemia, Sickle CellSleep Apnea SyndromesVascular DiseasesHumansAcute chest syndromeLung functionPulmonary hypertensionSickle cell cardiomyopathySickle cell diseaseSleep-disordered breathing

Identifiers

PMID36400540
PMCPMC10323820
OpenAlexW4309103887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.